Subject(s)
Intracellular Signaling Peptides and Proteins/genetics , Scleroderma, Systemic/genetics , Signal Transduction/genetics , Case-Control Studies , Gene Expression Profiling , Humans , Interferons/metabolism , Nitric Oxide Synthase Type II/metabolism , Scleroderma, Systemic/blood , Syndrome , Toll-Like Receptors/metabolismABSTRACT
OBJECTIVE: To determine the type and frequency of physical therapy (PT) prescribed by physicians for patients in the registry of the German Network for Systemic Sclerosis. METHODS: The data for 4,252 patients were analyzed using descriptive statistics, chi-square tests, and odds ratios (ORs). RESULTS: Overall, 37.4% of patients (1,590 of 4,252) received PT at the end of a yearly follow-up. The most frequently used type of PT was lymphatic drainage (n = 1,061, 36.8%), followed by exercise therapy (n = 1,047, 36.3%) and heat therapy (n = 689, 23.9%). More than three-fourths of treated patients (82%) received 1 or 2 different forms of PT simultaneously. The prescription of PT was associated with the extent of skin fibrosis as measured by the modified Rodnan skin thickness score (<10 [41.8% of patients], 11-20 [55.8% of patients], and >21 [63.9% of patients]; P < 0.001). Patients with musculoskeletal involvement (e.g., arthritis, muscle weakness, joint contractures, tendon friction rubs) had a higher chance of receiving PT than patients without these symptoms, with corresponding ORs ranging from 1.96 (95% confidence interval [95% CI] 1.69-2.28) for joint contractures to 3.83 (95% CI 2.89-5.08) for arthritis. When comparing the type of PT prescription across the initial and all follow-up visits from 2003 to 2017, significant alterations with a decreasing frequency of patients receiving PT could be observed (P = 0.001). CONCLUSION: To our knowledge, this is the first study reporting the use of PT in patients with systemic sclerosis (SSc) in a large cohort. Although SSc is characterized by considerable disability and restriction of motion, <40% of patients received PT.
Subject(s)
Patient Acceptance of Health Care/statistics & numerical data , Physical Therapy Modalities/statistics & numerical data , Scleroderma, Systemic/therapy , Severity of Illness Index , Chi-Square Distribution , Cohort Studies , Disability Evaluation , Female , Germany , Humans , Male , Middle Aged , Odds Ratio , Registries , Scleroderma, Systemic/pathologySubject(s)
Exanthema , Skin Abnormalities , Abdomen , Exanthema/diagnosis , Humans , Skin , Skin Abnormalities/diagnosisSubject(s)
Clarithromycin/therapeutic use , Crohn Disease/diagnosis , Diagnostic Errors , Mycobacterium Infections, Nontuberculous/diagnosis , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Female , Humans , Mycobacterium Infections, Nontuberculous/drug therapy , Nose , Young AdultABSTRACT
Digital ulcers (DU's) are one of the main symptoms of systemic scleroderma and occur in approximately 60% of all scleroderma patients. Due to possible complications such as infections, gangrene or amputation, they require regular medical attention and a good wound treatment by doctors and nursing staff. A definition of DU's has not yet been established. In 2009 the European League Against Rheumatism (EULAR) published guidelines for the treatment of DU's. An improvement of the healing of active ulcers has been described with Iloprost. Bosentan significantly reduced the frequency of occurrence of new DU's. In some small studies PDE-5 inhibitors appear helpful. Further studies with other therapeutic approaches will follow in the next few years.
Subject(s)
Iloprost/therapeutic use , Phosphodiesterase 5 Inhibitors/therapeutic use , Scleroderma, Systemic/complications , Scleroderma, Systemic/therapy , Skin Ulcer/etiology , Skin Ulcer/therapy , Sulfonamides/therapeutic use , Bosentan , Fingers/pathology , Hand Dermatoses/diagnosis , Hand Dermatoses/etiology , Hand Dermatoses/therapy , Humans , Scleroderma, Systemic/diagnosis , Skin Ulcer/diagnosis , Wound Healing/drug effectsABSTRACT
Contractions of an echinoderm (sp. Sclerodactyla briareus) smooth muscle, the longitudinal muscle of the body wall (LMBW), were evoked by acetylcholine (ACh) and agonists: epibatidine, muscarine and nicotine (in order of force generation: ACh>muscarine=epibatidine>nicotine). ACh-induced contractions were blocked by atropine by 50%, and methoctramine, by 30%. ACh responses were also blocked by 25% by methyllycaconitine (MLA) but not by D-tubocurarine (dTC). Muscarine initiated large contractions that were completely blocked by atropine. To elucidate possible muscarinic ACh receptor (mAChR) subtypes, muscarinic agonists (oxotremorine, pilocarpine) and antagonists (methoctramine, pirenzepine) were tested. Oxotremorine, pilocarpine, and pirenzepine each enhanced resting tonus and potentiated ACh-induced contractions (order of potency: pilocarpine>oxotremorine=pirenzepine). Muscarine, oxotremorine or pirenzepine generated phasic, rhythmic contractions. Nicotine-induced contractions were almost completely blocked by dTC but were not altered by atropine. Large contractions evoked by epibatidine were potentiated by dTC whereas atropine had no effect on them. MLA blocked spontaneous rhythmicity. Cholinesterase inhibitors, neostigmine or physostigmine, caused marked potentiation of ACh-induced contractions and initiated rhythmic slow wave contractions in previously quiescent muscles. The present pharmacological evidence points to the co-existence of excitatory nicotinic ACh receptor (nAChRs) and mAChRs where nAChRs possibly modulate tone, and the mAChRs initiate and enhance rhythmicity.